Massachusetts is home to a thriving pharmaceutical industry, with leading companies pushing the boundaries of drug discovery and biopharmaceutical advancements. From cannabinoid-based therapies by Targeted Pharmaceuticals in Worcester to oncology-focused innovations by TESARO in Waltham, these firms are at the forefront of cutting-edge research in personalized medicine and biotech. Investment opportunities abound in sectors such as oncology, neurology, and antimicrobial resistance, driven by Massachusetts' robust ecosystem of publicly traded companies and dynamic startups.
VDA Pharma, Inc. specializes in the manufacturing of biopharmaceuticals focused on HIV treatment, leveraging innovative approaches to develop effective therapies in the pharmaceutical industry.
ARIAD Pharmaceuticals specializes in pharmaceutical manufacturing with a focus on oncology and innovative drug development, leveraging biotechnology to advance cancer treatments.
Targeted Pharmaceuticals specializes in cannabinoid-based drug discovery and personalized medicine within the pharmaceutical manufacturing industry, focusing on innovative approaches to developing tailored therapeutic solutions.
Specializing in biotechnology research, Samyang Biopharm USA focuses on out-licensing innovative nucleic acid drug delivery systems and aims to establish partnerships and co-development ventures with pharmaceutical firms in the U.S.
Mispro specializes in providing AAALAC-accredited contract vivarium services for preclinical rodent studies, catering to biopharmaceutical research organizations with comprehensive animal care and compliance solutions. Its innovative approach includes offering dedicated vivarium space and specialized services that enhance the efficiency of biomedical and pharmaceutical research.
BioXchange is a leading networking organization in the biotechnology research sector, focused on connecting individuals and companies within the life sciences community through specialized events. It leverages its extensive network to foster collaboration across various industry sectors, including pharmaceuticals and drug discovery.
NeuForm Pharmaceuticals specializes in innovative drug discovery within the biopharmaceutical sector, developing proprietary and patent-protected candidates targeting oncology, neurology, immunology, and metabolic diseases. The organization emphasizes collaboration with top academic and clinical experts to deliver best-in-class medicines to patients.
Arsanis specializes in biotechnology research, focusing on innovative solutions in the pharmaceutical sector. The firm is positioned for growth following its merger with X4 Pharmaceuticals, enhancing its capabilities in developing advanced therapeutic options.
An independent, academic research center focused on enhancing the quality and efficiency of pharmaceutical and biopharmaceutical development, regulation, and utilization through strategic information and innovative research. It serves as a vital resource for stakeholders in the industry, regulatory agencies, and public policy, while fostering dialogue on critical issues affecting drug development globally.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative antiviral therapies for COVID-19 and severe viral diseases, addressing critical unmet medical needs in the biotechnology research industry.
Anthos Therapeutics is a clinical-stage biopharmaceutical entity dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, leveraging a unique blend of biotech agility and pharmaceutical rigor.
Ra Pharmaceuticals specializes in pharmaceutical manufacturing, focusing on innovative therapies for rare diseases. Its unique approach includes the development of peptide-based treatments, enhancing the effectiveness and precision of drug delivery.
Prilenia is a clinical-stage biotechnology firm dedicated to developing innovative treatments for neurodegenerative and neurodevelopmental disorders, with a focus on its lead asset, Pridopidine, a first-in-class oral drug candidate. The firm is actively conducting advanced clinical trials for Huntington’s disease and ALS, leveraging an established safety profile to address significant unmet medical needs.
Javelin Biotech specializes in biotechnology research, developing predictive drug discovery platforms that integrate human and computational biology to enhance preclinical drug discovery and increase drug approval rates.
CKP Therapeutics is a biotechnology research firm dedicated to developing innovative molecules and combination therapies aimed at treating metastatic cancer and overcoming drug resistance. Its research-intensive approach positions it at the forefront of cancer therapeutics.
Accellient Partners specializes in biotechnology research, offering integrated drug development services that encompass regulatory consulting, project management, and compliance support. Their innovative approach minimizes risks and costs while accelerating development timelines, making them a preferred partner for biopharmaceutical and investment firms navigating the complex drug development landscape.
PharmaEssentia specializes in biotechnology research, focusing on the development of innovative biologics for hematology, oncology, and immunology, with a commitment to improving patient outcomes in rare and orphan diseases. Its unique approach combines deep scientific expertise with a dedication to advancing drug development in the biopharmaceutical sector.
Wild Biotech is a biotechnology research firm specializing in drug discovery, leveraging innovative approaches to develop resilient therapeutic solutions.
Engaged in biotechnology research, Synspira Therapeutics focuses on innovative therapeutic solutions, emphasizing advancements in treatment methodologies.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm specializing in the development of innovative RNA-modulating drug candidates aimed at treating rare and ultra-rare diseases caused by premature stop codons. Their lead product, ELX-02, is designed to enhance protein synthesis by enabling ribosomes to bypass these genetic mutations, addressing significant challenges in conditions like cystic fibrosis and cystinosis.
CervoMed is a clinical-stage therapeutics firm specializing in the development of CNS-focused treatments for neurodegenerative diseases, leveraging a robust development pipeline to advance innovative solutions in the pharmaceutical manufacturing industry.
NeuroCores, Inc. is a preclinical-stage biopharmaceutical firm specializing in the development of treatments for rare pediatric neurological and neurodegenerative disorders. Its innovative approach includes the use of plasmalogen derivatives, which exhibit strong anti-neuroinflammatory and neurogenesis effects, positioning the firm as a leader in addressing critical unmet medical needs in this niche market.
TESARO is an oncology-focused biopharmaceutical firm dedicated to enhancing the cancer care experience through innovative drug development and commercialization. Their mission emphasizes a patient-first approach, fostering a culture of unconditional care and commitment to advancing oncology treatments.
Immunocan specializes in biotechnology research, focusing on innovative gene-edited animal platforms for the discovery of fully human and alpaca antibodies, enhancing antibody drug R&D across diverse scenarios.
Trevie Research specializes in oncology-focused clinical development and trial management, offering expert advisory services in biopharma drug development and commercialization. The firm leverages extensive experience and strong relationships with key opinion leaders to support Phase I/II drug development programs for biotech, pharmaceutical, and non-profit organizations.
Novelion Therapeutics focuses on developing innovative biopharmaceuticals aimed at establishing new standards of care for rare diseases, with a diverse portfolio that includes treatments for metabolic disorders and ongoing research into therapies for inherited retinal diseases. Their commitment to advancing science and clinical development distinguishes them in the biotechnology research industry.
Dyax specializes in biotechnology research, focusing on innovative approaches to develop therapies for rare diseases. Its expertise in this niche area enhances its contributions to the biotechnology industry.
Aurora Biopharma, Inc. specializes in research services within the biopharmaceutical industry, focusing on innovative approaches to drug development and therapeutic solutions.
Oxeia Biopharmaceuticals is focused on developing innovative therapeutics for mild traumatic brain injury (concussion) and related neuro-metabolic dysfunction, with a clinical-stage drug, OXE103, currently undergoing Phase 2 trials. Their unique approach addresses a significant gap in treatment options for concussion patients, emphasizing the need for more than just rest.
Augment Biologics is engaged in biotechnology research, focusing on leveraging advancements in glycobiology to innovate and enhance biologic drug development.
Updated on
Save time, improve accuracy, and get ahead of the competition with Cenco.ai.
Get startedTop Companies Like Divvy Homes for Innovative Home Financing
Explore top innovative home financing companies like Divvy Homes, providing unique solutions for modern buyers in the U.S.
Top 22 Chicken Fast Food Companies
Explore the top 22 chicken fast food companies in the U.S., showcasing unique flavors and dining experiences across multiple regions.
Top 26 Gas Station Companies
Explore the Top 26 Gas Station Companies in the U.S., focusing on innovative fuel solutions and customer service in states like New York, Texas, and California.